MRC PHRU conducts large-scale observational studies, randomised trials, and meta-analyses of randomised trials in vascular disease. These programmes are made possible by innovative methodological work conducted in two cross-cutting themes: Big Data and statistical approaches to epidemiological studies and Laboratory methods for epidemiological studies.
The China Kadoorie Biobank is a study of over 500,000 volunteers recruited from ten areas across China, with data from questionnaires, physical measurements, and long-term storage of blood samples.
Diverse Cohorts focus primarily on five large-scale prospective studies: the Mexico City Prospective Study (with stored blood samples) and four studies in diverse populations worldwide (without stored blood samples). In total, these five studies have recruited more than 1.4 million people and accumulated follow-up on 200,000 deaths.
Aim to study treatments that can produce sustained changes in risk factors that are known or suspected causes of such diseases, such as blood low-density lipoprotein (LDL) cholesterol (e.g. the 20,000 patient Heart Protection Study) and high-density lipoprotein (HDL) cholesterol (e.g. the THRIVE and REVEAL trials), or which are known to interrupt a disease mechanism (e.g. aspirin in the ASCEND trial of 15,000 people with diabetes mellitus).
We coordinate large collaborative meta-analyses of vascular disease trials by collecting and analysing individual patient data from all randomised trials that have addressed the same or a similar question. For example, we coordinate the Cholesterol Treatment Trialists’ (CTT) Collaboration, which has helped to determine the effects of reducing LDL cholesterol with statin therapy.